DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A STUDY TO LEARN HOW THE STUDY MEDICINE CALLED PF-07293893 AFFECTS MUSCLE BIOMARKERS OF HEALTHY ADULTS

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07293893
Drug: Placebo

First Posted Date: 2024-05-14

Last Posted Date: 2024-11-20

Lead Sponsor: Pfizer

Target Recruit Count: 31

Registration Number: NCT06413693

Locations: 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
🇺🇸
Research Centers of America, Hollywood, Florida, United States

Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine

Completed

Conditions: Migraine Disorders

First Posted Date: 2024-05-14

Last Posted Date: 2025-01-13

Lead Sponsor: Pfizer

Target Recruit Count: 528

Registration Number: NCT06412965

Locations: 🇺🇸
Pfizer, New York, New York, United States

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

Recruiting

Conditions: Colitis, Ulcerative

Interventions: Drug: Etrasimod

First Posted Date: 2024-05-03

Last Posted Date: 2024-11-20

Lead Sponsor: Pfizer

Target Recruit Count: 300

Registration Number: NCT06398626

Locations: 🇺🇸
BI Research Center, Houston, Texas, United States
🇺🇸
Reddy GI Associates, Mesa, Arizona, United States
🇺🇸
Amicis Research Center, Valencia, California, United States

and more 10 locations

A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants

Phase 1

Not yet recruiting

Conditions: Biological Availability
Healthy Participants

Interventions: Drug: Nirmatrelvir/ritonavir
Drug: Paxlovid

First Posted Date: 2024-05-02

Last Posted Date: 2024-05-02

Lead Sponsor: Pfizer

Target Recruit Count: 28

Registration Number: NCT06397144

A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-06954522 IR (Formulation 1)
Drug: PF-06954522 MR (Formulation 2)
Drug: PF-06954522 MR (Formulation 3)

First Posted Date: 2024-05-01

Last Posted Date: 2024-10-08

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT06393517

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
🇺🇸
Pfizer Clinical Research Unit, New Haven, Connecticut, United States

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

Active, not recruiting

Conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Interventions: Drug: Tafamidis

First Posted Date: 2024-05-01

Last Posted Date: 2025-05-08

Lead Sponsor: Pfizer

Target Recruit Count: 50

Registration Number: NCT06393465

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Oral [14C] PF-06821497
Drug: Oral PF-06821497
Drug: IV [14C] PF-06821497

First Posted Date: 2024-04-30

Last Posted Date: 2025-01-23

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT06392230

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Ritlecitinib

First Posted Date: 2024-04-17

Last Posted Date: 2024-08-28

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT06369454

Locations: 🇺🇸
Scintipharma - Lexington - Maywick View Lane, Lexington, Kentucky, United States

Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)

Recruiting

Conditions: Eczema
Immune System Diseases
Skin Diseases
Dermatitis, Atopic
Janus Kinase Inhibitors
Dermatitis

First Posted Date: 2024-04-08

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 200

Registration Number: NCT06353087

Locations: 🇨🇳
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
🇨🇳
Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan
🇨🇳
MacKay Memorial Hospital, Taipei City, Taiwan

and more 5 locations

A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: single dose of vepdegestrant as tablet formulation (Treatment A)
Drug: single dose of vepdegestrant as tablet formulation (Treatment B)
Drug: single dose of vepdegestrant as tablet formulation (Treatment C)

First Posted Date: 2024-04-04

Last Posted Date: 2024-10-01

Lead Sponsor: Pfizer

Target Recruit Count: 52

Registration Number: NCT06347861

Locations: 🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy